Reciprocal Binding of CTCF and BORIS to the NY-ESO-1 Promoter Coincides with Derepression of this Cancer-Testis Gene in Lung Cancer Cells
- 1 September 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (17) , 7763-7774
- https://doi.org/10.1158/0008-5472.can-05-0823
Abstract
Regulatory sequences recognized by the unique pair of paralogous factors, CTCF and BORIS, have been implicated in epigenetic regulation of imprinting and X chromosome inactivation. Lung cancers exhibit genome-wide demethylation associated with derepression of a specific class of genes encoding cancer-testis (CT) antigens such as NY-ESO-1. CT genes are normally expressed in BORIS-positive male germ cells deficient in CTCF and meCpG contents, but are strictly silenced in somatic cells. The present study was undertaken to ascertain if aberrant activation of BORIS contributes to derepression of NY-ESO-1 during pulmonary carcinogenesis. Preliminary experiments indicated that NY-ESO-1 expression coincided with derepression of BORIS in cultured lung cancer cells. Quantitative reverse transcription-PCR analysis revealed robust, coincident induction of BORIS and NY-ESO-1 expression in lung cancer cells, but not normal human bronchial epithelial cells following 5-aza-2′-deoxycytidine (5-azadC), Depsipeptide FK228 (DP), or sequential 5-azadC/DP exposure under clinically relevant conditions. Bisulfite sequencing, methylation-specific PCR, and chromatin immunoprecipitation (ChIP) experiments showed that induction of BORIS coincided with direct modulation of chromatin structure within a CpG island in the 5′-flanking noncoding region of this gene. Cotransfection experiments using promoter-reporter constructs confirmed that BORIS modulates NY-ESO-1 expression in lung cancer cells. Gel shift and ChIP experiments revealed a novel CTCF/BORIS-binding site in the NY-ESO-1 promoter, which unlike such sites in the H19-imprinting control region and X chromosome, is insensitive to CpG methylation in vitro. In vivo occupancy of this site by CTCF was associated with silencing of the NY-ESO-1 promoter, whereas switching from CTCF to BORIS occupancy coincided with derepression of NY-ESO-1. Collectively, these data indicate that reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter mediates epigenetic regulation of this CT gene in lung cancer cells, and suggest that induction of BORIS may be a novel strategy to augment immunogenicity of pulmonary carcinomas.Keywords
This publication has 49 references indexed in Scilit:
- Targeting the Epigenome for the Treatment and Prevention of Lung CancerSeminars in Oncology, 2005
- Familial cases of point mutations in the XIST promoter reveal a correlation between CTCF binding and pre-emptive choices of X chromosome inactivationHuman Molecular Genetics, 2005
- Promoter-Dependent Mechanism Leading to Selective Hypomethylation within the 5′ Region of Gene MAGE-A1 in Tumor CellsMolecular and Cellular Biology, 2004
- Epigenetics in human disease and prospects for epigenetic therapyNature, 2004
- Transgenic RNAi Reveals Essential Function for CTCF in H19 Gene ImprintingScience, 2004
- Cancer/testis‐associated genes: Identification, expression profile, and putative functionJournal of Cellular Physiology, 2003
- Comprehensive analysis of CpG islands in human chromosomes 21 and 22Proceedings of the National Academy of Sciences, 2002
- DNA methylation patterns and epigenetic memoryGenes & Development, 2002
- Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissuesInternational Journal of Cancer, 2001
- Transitions in histone acetylation reveal boundaries of three separately regulated neighboring lociThe EMBO Journal, 2001